Who’s next in line to succeed Ken Frazier as CEO of the Keytruda-blessed Merck?
When Merck waved off a looming forced retirement for Ken Frazier last September, the board cited flexibility in CEO transition as a key factor in the decision. Having Frazier — who’s also chairman of the company — around beyond his 65th birthday in 2019 would ensure they install the best person at the best time, they said.
The board has evidently begun that process with a clear preference for internal candidates, sources told Bloomberg. CFO Robert Davis, chief marketing officer Michael Nally, and chief commercial officer Frank Clyburn are all in the running, according to an insider.
Basic subscription required
Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.